Acinetobacter baumannii remains an important and difficult-to-treat pathogen whose
resistance patterns result in significant challenges for the clinician. Despite the prevalence …

Objectives The purpose of this study was to characterize decreased susceptibility to
tigecycline in clinical isolates of Escherichia coli obtained during Phase 3 clinical trials …

Abstract Objectives Multidrug-resistant Acinetobacter baumannii (MRAB) is an increasing
problem in UK hospitals, with many strains now resistant to all available antibiotics except …

Objectives This study presents 2016–2018 in vitro antimicrobial activity data and rates of
resistant phenotypes for clinical isolates of Acinetobacter baumannii from Africa/Middle East …

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-
associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is …

Acinetobacter baumannii, once considered a low-category pathogen, has emerged as an
obstinate infectious agent. The scientific community is paying more attention to this …

Background Acinetobacter baumannii infections are difficult to treat owing to the emergence
of various antibiotic resistant isolates. Because treatment options are limited for multidrug …

The first decade of the 20th century witnessed a surge in the incidence of infections due to
several highly antimicrobial-resistant bacteria in hospitals worldwide. Acinetobacter …

A 53‐year‐old woman experienced a multidrug‐resistant (MDR) Acinetobacter baumannii
urinary tract infection 5 months after undergoing kidney and liver transplantation. The …

The lack of active antimicrobial agents against multidrug-resistant (MDR) Acinetobacter
baumannii has posed great threat to the public health. Combination therapies with …